03 December 2024
03 December 2024
The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.
The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.
The submission for treating paediatric plaque psoriasis is supported by outcomes from the Phase III PROTOSTAR study in children.
PTC Therapeutics is set to obtain an upfront payment of $1bn.
The change comes as the company reaffirms its commitment to developing new off-the-shelf cellular immunotherapies.
The deal encompasses UCB's Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro.
The topical cream is currently being developed by researchers.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
